Results 291 to 300 of about 1,436,444 (347)
Some of the next articles are maybe not open access.
A single-cell atlas of CD19 chimeric antigen receptor T cells
Cancer Cell, 2023Li et al. present a resource of single-cell RNA sequencing (scRNA-seq) data from the infusion products of relapsed or refractory large B cell lymphoma (rrLBCL) patients treated with standard-of-care axicabtagene ciloleucel and identify features that are significantly different between products from responders and non-responders at 3-month followup by ...
Xubin, Li +12 more
openaire +2 more sources
CD19 regulates B cell antigen receptor-mediated MHC class II antigen processing
Vaccine, 1999In B cells, the processing of antigens in the context of MHC class II molecules is initiated by the binding of antigen to the B cell antigen receptor (BCR). The BCR serves two roles in antigen processing, signaling for enhanced processing and endocytosing bound antigen.
N M, Wagle, J H, Kim, S K, Pierce
openaire +2 more sources
Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells
Experimental Hematology, 2007Preclinical and clinical trials are investigating the potential of T cells genetically modified to express a first-generation CD19-specific chimeric antigen receptor (CAR), designated CD19R, for adoptive immunotherapy of B-lineage leukemias and lymphomas.
Tontanai, Numbenjapon +5 more
openaire +2 more sources
Structure of the genes encoding the CD19 antigen of human and mouse B lymphocytes
Immunogenetics, 1992CD19 is a B lymphocyte cell-surface marker that is expressed early during pre-B-cell differentiation with expression persisting until terminal differentiation into plasma cells. CD19 is a member of the Ig gene superfamily with two extracellular Ig-like domains separated by a non-Ig-like domain, and with an extensive approximately 240 amino acid ...
L J, Zhou +3 more
openaire +2 more sources
Targeting Two Antigens Associated with B-ALL with CD19-CD123 Compound Car T Cell Therapy
Stem Cell Reviews and Reports, 2020Lulu E. Yan +17 more
semanticscholar +1 more source
Current Research in Translational Medicine
Relapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1). Here we report the results of a phase 2 study giving point of care produced CD19 CAR T- cells for r/r AML with aberrant expression of CD19 (NCT04257175).
Ivetta Danylesko +9 more
openaire +2 more sources
Relapsed/refractory (r/r) acute myeloid leukemia (AML) is associated with poor prognosis. CD19 is a B-cell marker, is aberrantly expressed in AML, mostly with t(8; 21)(q22; q22.1). Here we report the results of a phase 2 study giving point of care produced CD19 CAR T- cells for r/r AML with aberrant expression of CD19 (NCT04257175).
Ivetta Danylesko +9 more
openaire +2 more sources
CD19 AND CD22 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
2021ENGELS BORIS, GUIMARAES CARLA PATRICIA
openaire +4 more sources